Although the exact mechanism by which this SNP protects against MASLD is still unclear, anti-HSD17B13 therapies are ongoing in the setting of clinical trials [14,15]. This evidence concerns the gene HSD17B13 and metabolic dysfunction-associated steatotic liver disease.